跳至主要内容
临床试验/JPRN-UMIN000001191
JPRN-UMIN000001191已完成2 期

A phase II study of the remission induction and maintenance therapy by rituximab for rituximab naive low grade B cell lymphoma. - Inducion and maintenance therapy by rituximab for low grade B cell lymphoma.

Clinical Hematology Study Group of National Hospital Organization(CHSG-NHO)0 个研究点目标入组 42 人开始时间: 2008年6月20日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
42

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 79years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1.presence of central nervous invasion(clinical or pathological). 2.transformed patients (clinical or pathological). 3.past history of glaucoma. 4.past history of severe drug allergy. 5.HIV Ab positive or HTLV-1 Ab positive. 6.HBsAg positive, HBsAb positive, or HCV Ab positive. 7.severe cardiac disease 8.hepatic cirrhosis 9.uncontrollable diabetis melitus 10.patients with dialysis 11.lung fibrosis or interstitial pneumonitis 12.other active malignancies 13.pregnant or feeding female 14.severe mental disorder 15.systemic therapy with corticosteroid 16.judged for inappropriate with other reasons.

研究者

发起方
Clinical Hematology Study Group of National Hospital Organization(CHSG-NHO)

相似试验